Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Analysts See $-0.89 EPS

May 17, 2018 - By Ellis Scott

Analysts expect Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) to report $-0.89 EPS on June, 15.They anticipate $0.85 EPS change or 48.85 % from last quarter’s $-1.74 EPS. After having $-0.75 EPS previously, Biohaven Pharmaceutical Holding Company Ltd.’s analysts see 18.67 % EPS growth. The stock increased 0.60% or $0.18 during the last trading session, reaching $29.95. About 453,190 shares traded. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The company has market cap of $1.16 billion. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. It currently has negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.

More notable recent Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news were published by: Seekingalpha.com which released: “Your Daily Pharma Scoop: Biohaven Updates, MEIP Offering, Kite European Expansions” on May 17, 2018, also Streetinsider.com with their article: “Biohaven (BHVN) to Present Additional Phase 3 Rimegepant Data at AAN 2018 on April 22nd” published on April 19, 2018, Prnewswire.com published: “Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results” on May 15, 2018. More interesting news about Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) were released by: Prnewswire.com and their article: “Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS┬« Orally Dissolving Tablets for Patients …” published on May 09, 2018 as well as Seekingalpha.com‘s news article titled: “Biohaven announces secondary endpoint results from Phase 3 clinical trials BHV3000-301 and 302 of Rimegepant” with publication date: April 23, 2018.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.